XY0206

XY0206 is a novel, orally administered small molecule that acts as a selective inhibitor of FMS-like tyrosine kinase 3 (FLT3). It targets and inhibits FLT3 activity, thereby suppressing the proliferation of FLT3-expressing cancer cells. XY0206 has demonstrated potent anti-leukemic activity in preclinical models and early clinical trials, particularly against acute myeloid leukemia (AML) with FLT3 internal tandem duplication mutations (FLT3-ITD). The drug is being developed primarily for relapsed or refractory AML and is also under investigation for first-line treatment in combination with chemotherapy. Additionally, there are indications it may be explored for autoimmune diseases. Clinical development includes multiple phase I/II and phase III studies to assess safety, efficacy, pharmacokinetics, and optimal dosing[1][2][4][5][7].